becton dickinson compani
summari report revenu larg in-
line street forecast underli growth trend softer
consensus/our expect total revenu
slightli consensu essenti in-lin
forecast howev compar growth ex-fx pro forma bcr
came estim ep beat
consensu estim upsid vs
model primarili driven higher gross margin net
expens partli off-set higher tax rate rais
compar revenu growth guidanc
impli meaning step growth
believ guidanc doabl
expect revers headwind base manag
confid order pipelin understand dose
skeptic among investor believ new ep
guidanc reason despit small fx
headwind estim sale growth ep
rais price target base
ep estim ebitda forecast
sale essenti line growth softer
expect report total revenu
compar growth growth slight deceler
estim bd medic growth
similar adjust us dispens chang
faster growth md off-set slower growth
diabet pharma system bd lifesci ls growth
also similar adjust manufactur
disrupt exclud impact strong flu season bd
intervent growth slow reflect
softer growth across three sub-seg manag note
sever factor weigh growth time order
inventori channel dynam adjust event
boost overal growth closer
margin ep beat expect ep came
consensu estim rel
model ep beat driven higher gross margin vs
estim lower net expens vs
estim partli off-set higher tax rate vs
estim robust gross margin includ fx
benefit underli y/yr improv driven
bcr acquisit note alreadi repaid
bcr-relat debt thu reduc interest expens q/q
like ad penni ep
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
top-lin guidanc impli meaning growth acceler rais
compar sale growth outlook impli growth
meaning step call follow manag express
confid growth outlook busi see bd medic growth impli
growth particular manag believ good visibl order
pipelin medic manag solut pharma system expect strong doubl digit
growth busi compar respect compani expect
bd intervent grow impli growth key growth driver
surgeri manag said hurt reduc purchas follow strong inventori
restock hurrican maria addit normal channel inventori also note easier
comp anniversari progel suppli disrupt bd ls expect solid growth
momentum continu growth rang consist normal ytd growth
nearli adjust strong flu season manufactur issu unadjust
ls guidanc growth impli growth least seem conserv us
report basi estim fx headwind vs tailwind
narrow ep guidanc seem reason expect ep rang
rais bottom-end rang base ytd report ep
impli ep midpoint rang current consensu
midpoint rang impli ep would flat sequenti expect faster top-lin growth
lower net interest expens off-set fx headwind tva dilut tariff impact ep
estim within guidanc rang
sever growth headwind note manag expect absorb/offset impact
yet provid guidanc manag note sever headwind face busi
next year estim fx repres tailwind estim becom
headwind impact tariff penni becom
tax rate could move higher due increment tax foreign earn manag
believ overcom offset off-set headwind compani expect
leverag benefit continu margin improv cost synergi bcr deal lower interest
expens compani also emphas track record absorb headwind seem confid
continu final note gore royalti due expir august
impact limit month thu minim continu
expect lower interest expens off-set dilut absenc gore royalti current estim
compar sale growth ep
develop pipelin remain solid lutonix btk file track look ahead launch
new alari pump includ enhanc featur see opportun gain increment market
share compani also expect launch addit iv solut freseniu agreement later
expect small contributor sale expect becom
meaning beyond addit molecul also note continu broaden
assay menu max lutonix btk below-the-kne compani complet
month follow believ remain track file fda earli late
compani also expect launch recent acquir everlinq endoavf system tva medic av
arterioven fistula earli manag believ could coupl hundr million dollar
product five year addit pipelin expect return progel barricor later
year could also help improv growth outlook late
becton dickinson compani
metricswfconsensusrevenu medic manag deliveri critic factset revenu fit incom compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut vs consensusactu vs consensu forma guidanc guidanc guidanc guidanc ex-fx medic ex-fx life scienc ex-fx intervent ex-fx market ex-fx dd dd ddchina ex-fx market ex-fx ex-fx revenu adjust divestitur includ us dispens chang impact hurrican maria bcr sourc compani report secur llc estim stand-alon medic technolog
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost
save accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ well posit acceler top- bottom-lin growth bcr acquisit
potenti upsid
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu pro forma ex-fx basi
becton dickinson compani incom statement fy end sep million except per share data -- stand-alonepro forma bcr qtr life revenu revenu revenu pf product amort expense- gross total oper oper interest incom interest incom gore royalti expir aug incom expens total non-op incom expens pre-tax incom tax expens net prefer dividend net incom common method share outstand method convert share outstand marginsgross op ep method op ep method compani report secur llc estim becton dickinson compani
